The future of cancer immunotherapy is looking brighter than ever! A new study conducted by researchers from the University of Illinois at Chicago has revealed a promising new approach that uses mRNA nanovaccines to trigger an anti-tumor immune response. The study, which was recently published in the journal Nature Communications, details the development of a rational mRNA nanovaccine that can be used to target and destroy tumor cells. The nanovaccine is composed of a small, non-coding RNA molecule that is able to penetrate the tumor cell membrane and activate an anti-tumor immune response. The study also showed that the nanovaccine was able to induce a strong, sustained, and specific anti-tumor immune response in both animal models and human patients. This new approach to cancer immunotherapy could revolutionize how we treat the disease and offer a novel way to fight cancer without the use of toxic chemotherapy or radiation.

Read Full Article Here

source: Phys.org